BerGenBio Investor Relations Material
Latest events
Q4 2024
BerGenBio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from BerGenBio
Access all reports
BerGenBio ASA is a clinical-stage biopharmaceutical company based in Bergen, Norway, focused on developing innovative therapies for aggressive diseases such as cancer and severe respiratory infections. The company specializes in AXL kinase inhibitors, with its lead product, Bemcentinib, currently undergoing clinical trials for non-small cell lung cancer (NSCLC) and severe respiratory conditions. Another key asset, Tilvestamab, is a monoclonal antibody targeting AXL, being investigated for the treatment of ovarian cancer. BerGenBio is leveraging its expertise in AXL biology to create treatments that can potentially improve outcomes in diseases characterized by drug resistance and immune evasion. The company's strategy includes partnerships with clinical sites and biopharma firms to advance its drug pipeline. The company is headquartered in Bergen, Norway, and its shares are traded on the Oslo Stock Exchange.
Key slides for BerGenBio
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
BGBIO
Country
🇳🇴 Norway